Head to Head Contrast: Blueprint Medicines (BPMC) and Its Rivals
Blueprint Medicines (NASDAQ: BPMC) is one of 181 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Blueprint Medicines to related companies based on the strength of its profitability, valuation, earnings, analyst recommendations, dividends, risk and institutional ownership.
This is a breakdown of current ratings for Blueprint Medicines and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Blueprint Medicines Competitors||545||2422||6640||131||2.65|
Blueprint Medicines currently has a consensus target price of $83.78, indicating a potential upside of 9.10%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 32.30%. Given Blueprint Medicines’ rivals higher probable upside, analysts plainly believe Blueprint Medicines has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares Blueprint Medicines and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Blueprint Medicines||$27.77 million||-$72.49 million||-22.45|
|Blueprint Medicines Competitors||$217.36 million||-$39.57 million||-67.87|
Blueprint Medicines’ rivals have higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
83.5% of Blueprint Medicines shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 3.4% of Blueprint Medicines shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Blueprint Medicines and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Blueprint Medicines Competitors||-4,721.96%||-493.38%||-41.99%|
Blueprint Medicines beats its rivals on 7 of the 12 factors compared.
About Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.